Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT M FRIEDMAN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1497842314
CMS profile
203310
Location
LAKELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$11,089.59

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,292.00 3
Food and Beverage $2,657.90 46
Travel and Lodging $1,139.69 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT M FRIEDMAN

NPI 1497842314 · CMS profile ID 203310

Allopathic & Osteopathic Physicians / Ophthalmology

LAKELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497842314?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT M FRIEDMAN, NPI 1497842314, CMS profile ID 203310. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497842314?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SCOTT M FRIEDMAN, NPI 1497842314, CMS profile ID 203310. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497842314?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SCOTT M FRIEDMAN, NPI 1497842314, CMS profile ID 203310, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1497842314?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $11,089.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $24.6801/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040547735 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $985.35 17
PY2020 $544.90 12
PY2021 $1,022.71 24
PY2022 $2,309.61 33
PY2023 $11,089.59 51
PY2024 $4,453.99 34
PY2025 $4,802.43 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,961.21 1
PY2025 Principal investigator $609,306.97 332
PY2024 Principal investigator $37,891.21 4
PY2023 Principal investigator $440,065.39 27
PY2022 Principal investigator $94,235.70 8
PY2021 Principal investigator $369,216.80 25
PY2020 Principal investigator $39,194.46 54
PY2019 Recipient $2,436.66 10
PY2019 Principal investigator $88,297.70 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

333 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $2,926.80 12/24/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/19/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/19/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/19/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/19/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278032
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 12/17/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681070
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681072
Principal investigator 1 Boehringer Ingelheim International GmbH $91.64 12/17/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681074
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 12/17/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681076
Principal investigator 1 Boehringer Ingelheim International GmbH $3,820.16 12/11/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681058
Principal investigator 1 Boehringer Ingelheim International GmbH $1,909.12 12/11/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681060
Principal investigator 1 Boehringer Ingelheim International GmbH $3,820.16 12/11/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681062
Principal investigator 1 Ocular Therapeutix, Inc. $22,222.00 12/05/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 12/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266995
Principal investigator 1 Boehringer Ingelheim International GmbH $6,044.80 11/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681052
Principal investigator 1 Ocular Therapeutix, Inc. $9,875.70 11/21/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234075
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.80 11/20/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681046
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 11/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681048
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.80 11/06/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681050
Principal investigator 1 Boehringer Ingelheim International GmbH $5,165.44 11/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681054
Principal investigator 1 Boehringer Ingelheim International GmbH $5,165.44 11/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681056
Principal investigator 1 ABBVIE INC. $2,994.74 10/30/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202519885
Principal investigator 1 Boehringer Ingelheim International GmbH $4,800.64 10/29/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681026
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 10/29/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681030
Principal investigator 1 Ocular Therapeutix, Inc. $8,178.30 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 10/29/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254289
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681064
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 10/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681066
Principal investigator 1 Boehringer Ingelheim International GmbH $93.96 10/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681068
Principal investigator 1 Boehringer Ingelheim International GmbH $3,580.80 10/22/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681028
Principal investigator 1 Boehringer Ingelheim International GmbH $4,857.60 10/22/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,318.46 10/17/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,263.22 10/17/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,239.23 10/17/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251209
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234087
Principal investigator 1 Boehringer Ingelheim International GmbH $6,044.80 10/09/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681042
Principal investigator 1 Boehringer Ingelheim International GmbH $3,580.80 10/06/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681020
Principal investigator 1 Boehringer Ingelheim International GmbH $4,112.00 10/06/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681034
Principal investigator 1 Boehringer Ingelheim International GmbH $4,857.60 10/06/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681040
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681022
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681024
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681032
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681038
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/03/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,069.47 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,069.47 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.72 10/03/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245335
Principal investigator 1 Ocular Therapeutix, Inc. $12,258.90 10/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234068
Principal investigator 1 Boehringer Ingelheim International GmbH $1,898.00 09/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680988
Recipient Regeneron Pharmaceuticals, Inc. $2,961.21 09/25/2025 Covered Recipient Physician EYLEA CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/25/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242533
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 09/24/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680964
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 09/24/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680966
Principal investigator 1 Boehringer Ingelheim International GmbH $89.32 09/24/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680968
Principal investigator 1 Boehringer Ingelheim International GmbH $3,710.08 09/15/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,003.17 09/15/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,003.17 09/15/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,003.17 09/15/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 09/15/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,003.17 09/15/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236936
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680972
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680974
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680976
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680978
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680980
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680982
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680984
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680986
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680990
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680992
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680994
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680996
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680998
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681000
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681002
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681004
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681006
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681008
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681010
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681012
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681014
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681016
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/10/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681018
Principal investigator 1 ABBVIE INC. $7,015.46 09/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202507069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,956.00 09/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,700.00 09/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 09/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,200.00 09/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233236
Principal investigator 1 Boehringer Ingelheim International GmbH $137.62 08/28/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681080
Principal investigator 1 Boehringer Ingelheim International GmbH $4,374.40 08/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680952
Principal investigator 1 Boehringer Ingelheim International GmbH $78.44 08/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220681078
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 08/21/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680950
Principal investigator 1 Boehringer Ingelheim International GmbH $4,112.00 08/18/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680954
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 08/18/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680956
Principal investigator 1 Ocular Therapeutix, Inc. $3,238.20 08/13/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234059
Principal investigator 1 Ocular Therapeutix, Inc. $12,812.40 08/13/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 08/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 08/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 08/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 08/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184225939
Principal investigator 1 Ocular Therapeutix, Inc. $9,000.00 08/01/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234055
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 07/28/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.89 07/24/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $430.00 07/24/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.53 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.53 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 07/16/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215046
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 07/02/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680946
Principal investigator 1 Ocular Therapeutix, Inc. $25,059.60 07/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234051
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680948
Principal investigator 1 Boehringer Ingelheim International GmbH $3,820.16 06/24/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680932
Principal investigator 1 Boehringer Ingelheim International GmbH $3,710.08 06/20/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680926
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.80 06/20/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680928
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 06/20/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680930
Principal investigator 1 Boehringer Ingelheim International GmbH $5,165.44 06/20/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680934
Principal investigator 1 Ocular Therapeutix, Inc. $27,971.10 06/18/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234045
Principal investigator 1 Boehringer Ingelheim International GmbH $4,857.60 06/16/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.53 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.53 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.53 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,038.53 06/02/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201517
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680960
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680940
Principal investigator 1 Boehringer Ingelheim International GmbH $25.52 05/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680942
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 05/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680944
Principal investigator 1 Boehringer Ingelheim International GmbH $4,374.40 05/16/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680936
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,624.18 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,430.78 04/23/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186157
Principal investigator 1 Boehringer Ingelheim International GmbH $6,044.80 04/14/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680918
Principal investigator 1 Boehringer Ingelheim International GmbH $3,820.16 04/11/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680916
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680920
Principal investigator 1 Boehringer Ingelheim International GmbH $3,710.08 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680868
Principal investigator 1 Boehringer Ingelheim International GmbH $3,710.08 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680870
Principal investigator 1 Boehringer Ingelheim International GmbH $3,820.16 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680872
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.80 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680874
Principal investigator 1 Boehringer Ingelheim International GmbH $4,112.00 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680876
Principal investigator 1 Boehringer Ingelheim International GmbH $4,857.60 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680878
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.40 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680880
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.80 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680882
Principal investigator 1 Boehringer Ingelheim International GmbH $5,165.44 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680884
Principal investigator 1 Boehringer Ingelheim International GmbH $4,374.40 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680886
Principal investigator 1 Boehringer Ingelheim International GmbH $3,820.16 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680888
Principal investigator 1 Boehringer Ingelheim International GmbH $4,857.60 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680890
Principal investigator 1 Boehringer Ingelheim International GmbH $4,374.40 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680892
Principal investigator 1 Boehringer Ingelheim International GmbH $4,112.00 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680894
Principal investigator 1 Boehringer Ingelheim International GmbH $4,857.60 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680896
Principal investigator 1 Boehringer Ingelheim International GmbH $5,165.44 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680898
Principal investigator 1 Boehringer Ingelheim International GmbH $5,165.44 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680900
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.80 03/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,624.18 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,624.18 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,624.18 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,624.18 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,624.18 03/12/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173234
Principal investigator 1 Ocular Therapeutix, Inc. $15,286.50 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.38 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.31 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.25 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.50 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.75 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.12 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.42 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184157983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $358.17 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $449.30 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.38 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $366.27 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.31 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.25 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $348.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.12 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.47 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184158339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $348.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $348.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.25 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.50 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $521.72 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.75 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.12 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.38 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.47 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.31 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184166951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.38 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $416.90 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.15 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.47 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $416.90 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.47 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $348.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.50 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.25 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.47 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184167497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $521.72 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $431.25 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.75 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.12 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $354.38 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.31 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184169778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $521.72 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.75 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.50 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $521.72 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $348.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $348.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $393.28 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.12 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.31 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170500
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $521.72 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $427.03 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $388.12 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $434.53 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.47 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $340.78 03/07/2025 Non-covered Recipient Entity
FLORIDA RETINA CONSULTANTS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184170526
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680922
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 02/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680908
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 02/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680910
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 02/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680912
Principal investigator 1 Boehringer Ingelheim International GmbH $92.80 02/25/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680914
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680958
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 01/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680904
Principal investigator 1 Boehringer Ingelheim International GmbH $118.32 01/27/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680906
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Florida Retina Consultants PA
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220680866